Advertisement

Advertisement

colorectal cancer

USPSTF Issues New Recommendations for Colorectal Cancer Screening

As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening. In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...

colorectal cancer

SNMMI 2016: Pretargeted Radioimmunotherapy Eliminates Colorectal Cancer in Preclinical Studies

Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models (Scientific Paper...

colorectal cancer
solid tumors

Norwegian Study Shows Benefit of Aspirin as Secondary Prevention in Patients With Colorectal Cancer

A Norwegian population-based study reported in the Journal of Clinical Oncology by Bains et al showed that use of aspirin after diagnosis of colorectal cancer was associated with improved colorectal cancer–specific survival. Study Details In the population-based retrospective cohort study,...

colorectal cancer

ASCO 2016: Nivolumab Shows Promise in Refractory, Metastatic Anal Cancer

In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint inhibitor nivolumab (Opdivo) shows promise for the majority of patients with squamous cell carcinoma of the ...

colorectal cancer

Heinz-Josef Lenz, MD, and Marc Ychou, MD, on Treating mCRC With Initially Nonresectable Liver Metastases

Heinz-Josef Lenz, MD, of the University of Southern California, and Marc Ychou, MD, of the Centre Régional de Lutte Contre Le Cancer, discuss study findings on FOLFIRINOX combined with targeted therapy according to RAS status for colorectal cancer patients with initially nonresectable liver metastases (Abstract 3512).

colorectal cancer

Michael J. Overman, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Interim Results of the CheckMate 142 Trial

Michael J. Overman, MD, of the University of Texas MD Anderson Cancer Center, and John Marshall, MD, of Georgetown University Lombardi Comprehensive Cancer Center, discuss interim findings on nivolumab with or without ipilimumab in the treatment of patients with metastatic colorectal cancer with and without high microsatellite instability (Abstract 3501).

colorectal cancer

Alan P. Venook, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Analysis of CALGB-SWOG 80405

Alan Venook, MD, of the University of California, San Francisco, and John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, discuss the impact of primary tumor location on overall survival and progression-free survival in patients with advanced disease (Abstract 3504).

colorectal cancer

Study Finds Adding Adjuvant Oxaliplatin to Fluoropyrimidine of Benefit in Deficient Mismatch Repair Colon Cancer

In a French retrospective study reported in the Journal of the National Cancer Institute, Tougeron et al found that the addition of adjuvant oxaliplatin to fluoropyrimidine treatment improved disease-free survival in patients with stage III deficient mismatch repair colon cancer. Study Details...

colorectal cancer

DDW 2016: Rates of Colorectal Cancer Continue to Increase in Those Under 50

A new study shows the rate of colorectal cancer continues to increase in individuals under 50 years old, despite the fact that the overall rate of the disease has been declining in recent years. Following examination of more than 1 million colorectal cancer patient records over 10 years,...

colorectal cancer

DDW 2016: Low-Residue Diet Prior to Colonoscopy Shows Improved Tolerance and Bowel Preparation vs Clear Liquid Diet

A new study finds that patients who ate certain solid foods, considered “low residue,” were better prepared for their colonoscopies than individuals who followed the conventional liquid diet. Additionally, researchers saw that these patients who ate foods such as eggs, white bread,...

colorectal cancer

DDW 2016: Endoscopist’s Knowledge of Positive Cologuard Test Improves Colonoscopy Performance

An endoscopist's knowledge of a positive Cologuard test improves colonoscopy performance, according to a poster presentation by Johnson et al at Digestive Disease Week (DDW) 2016 (Abstract Su1044). Cologuard is an at-home, stool-DNA colorectal cancer screening test that has been approved by the...

colorectal cancer

Body Mass Index and Mortality in Patients With Colorectal Cancer

Overweight colorectal cancer patients were 55% less likely to die from their cancer than normal-weight patients who have the disease, according to a new Kaiser Permanente study published by Kroenke et al in JAMA Oncology. Of cancers affecting both men and women, colorectal cancer is the...

Colorectal Cancer

Site of Tumor Impacts Survival and Choice of Treatment in Metastatic Colorectal Cancer

In metastatic colorectal cancer, the anatomic location of the tumor within the colon appears to make a difference in overall survival as well as response to pivotal treatments, according to a retrospective analysis of the pivotal CALGB/SWOG 80405 (Alliance) trial.1 “While previous studies had...

colorectal cancer

Specific Version of the FCGR2A Gene Identifies Colorectal Cancer Patients Likely to Benefit Most From Cetuximab

Among patients with metastatic colorectal cancer harboring normal forms of the KRAS gene, only those who had two copies of a specific version of the FCGR2A gene (FCGR2A H/H) had a statistically significant increase in median overall survival when cetuximab (Erbitux) treatment was added to best...

colorectal cancer

ASCO 2016: Left- vs Right-Sided Primary Tumor Location Predicts Survival in Metastatic Colorectal Cancer

For a longer-form examination of these data, click here. A retrospective analysis from a large, federally funded clinical trial finds that the location of the primary tumor within the colon predicts survival and may help inform optimal treatment selection for patients with metastatic colorectal...

colorectal cancer

Study of SEER Data Identifies Racial/Ethnic Disparities in Survival in Patients With Young-Onset Colorectal Cancer

In a study of Surveillance, Epidemiology, and End Results (SEER) data reported in the Journal of Clinical Oncology, Holowatyj et al found that survival was significantly poorer in black vs white patients diagnosed with colorectal cancer between the ages of 20 and 49 years. Study Details The...

colorectal cancer

Little Apparent Activity of Cetuximab in Refractory Metastatic Colorectal Cancer With KRAS G13D Mutation

Cetuximab (Erbitux) exhibited little apparent activity in refractory metastatic colorectal cancer harboring the KRAS G13D mutation, according to the findings of the phase II Australasian Gastro-Intestinal Trials Group ICECREAM study, which were reported by Segelov et al in the Journal of Clinical...

colorectal cancer

Trastuzumab/Lapatinib Active in Refractory, KRAS Codon 12/13 Wild-Type, HER2-Positive Metastatic Colorectal Cancer

Dual HER2 inhibition with trastuzumab (Herceptin) and lapatinib (Tykerb) was active in patients with refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer, according to an Italian phase II trial reported by Sartore-Bianchi et al in The Lancet Oncology. Study Details...

colorectal cancer

New Study Suggests Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk

Long-term use of the cholesterol-lowering drugs statins does not appear to decrease a patient’s risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine published by Mamtani et al in PLOS Medicine. The observational analysis of over 100,000 patients’...

colorectal cancer

AACR 2016: Cologuard Detected Colorectal Cancer in Previously Unscreened Patients

A noninvasive colorectal cancer-screening test detected the disease in patients who had previously avoided more invasive screening measures, according to research presented by Prince et al at the 2016 AACR Annual Meeting (Abstract LB-296). The study of nearly 400 patients revealed four patients...

Colorectal Cancer

CDX2 in Stage II Colon Cancer: Ready for Prime Time?

In a recent issue of The New England Journal of Medicine, Dalerba et al published an impressive article describing a novel bioinformatics approach to identifying new prognostic and predictive biomarkers in patients with stage II and III colon cancer (see summary in this issue of The ASCO Post).1...

Colorectal Cancer

Transcription Factor CDX2 May Be a Prognostic Biomarker in Stage II and III Colon Cancer

In a study reported in The New England Journal of Medicine, Piero Dalerba, MD, of Columbia University, and colleagues found that absence of the transcription factor CDX2 was prognostic for poor outcome in patients with stage II and III colon cancer vs cancers with CDX2 expression.1 However,...

colorectal cancer

Increased Rate of Nonoperative Management of Rectal Adenocarcinoma

A National Cancer Database analysis reported by Ellis et al in the Journal of Clinical Oncology indicates a doubling in the use of chemoradiation only in patients with nonmetastatic rectal cancer over recent years. However, current evidence is insufficient to support such nonoperative management....

colorectal cancer

Next-Generation Sequencing Assay May Permit Accurate Detection of Mismatch Repair Deficiency in Colorectal Cancer

Use of a custom next-generation sequencing assay may accurately predict mismatch repair deficiency on the basis of mutational load in colorectal cancer, according to a report by Stadler et al in the Journal of Clinical Oncology. Study Details The study involved data from 224 patients with...

colorectal cancer

New Study Links Coffee Consumption to Decreased Risk of Colorectal Cancer

Researchers at the University of Southern California (USC) Norris Comprehensive Cancer Center of Keck Medicine of USC and Clalit National Israel Cancer Control Center have found that coffee consumption may be inversely associated with the risk of colorectal cancer. The findings by Schmit et...

colorectal cancer

Christopher Willett, MD, on Localized Rectal Cancer: Emerging Treatment Paradigms

Christopher Willett, MD, of Duke Cancer Center, discusses short and long courses of treatment, neoadjuvant chemotherapy with or without radiation, and organ preservation without surgery.

colorectal cancer

Alan Venook, MD, on Metastatic Colorectal Cancer: Choosing Optimal Treatment Strategies

Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.

colorectal cancer

Endoscopic Mucosal Resection Is an Alternative to Surgery in Most Patients With Complex Colon Polyps

Using the latest advances in endoscopic resection techniques, more than 75% of patients with complex colon polyps could avoid surgery for their polyp removal, according to new research from The University of Texas MD Anderson Cancer Center. The findings, published by Raju et al in Gastrointestinal ...

colorectal cancer

Japanese Trial Shows Reduced Risk of Subsequent Colorectal Adenomas and Polyps With Low-Dose Metformin

Treatment with low-dose metformin reduced the risk of metachronous colorectal adenomas and polyps over 12 months in nondiabetic patients who had undergone endoscopic polypectomy, according to a report by Higurashi et al in The Lancet Oncology. Study Details In the double-blind phase III trial,...

Colorectal Cancer

Patients Diagnosed With Stage I to III Rectal Cancer at Younger Age Have Increased Risk for Positive Lymph Nodes

Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact treatment...

Colorectal Cancer

Fecal Immunochemical Test Highly Sensitive and Effective When Used for Colorectal Cancer Annual Screening Programs

Annual screening with the fecal immunochemical test is highly sensitive for detecting colorectal cancer and “is feasible and effective for population-level colorectal cancer screening,” according to a large-scale retrospective cohort study assessing this test over four rounds of annual screening....

Colorectal Cancer

Expert Point of View: Wells Messersmith, MD

Wells Messersmith, MD, Professor and Head of Medical Oncology and Director of the Gastrointestinal Cancer Program, University of Colorado, Denver, discussed the two studies. Closer Look at STEAM Dr. Messersmith said the FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) vs FOLFOX...

Colorectal Cancer

Studies Evaluate Bevacizumab-Containing Regimens in Metastatic Colorectal Cancer

Two trials reported at the 2016 Gastrointestinal Cancers Symposium evaluated bevacizumab (Avastin)-containing regimens in the first-line treatment of metastatic colorectal cancer and supported some, but not all, previous findings. The STEAM trial found some numerical differences but no...

colorectal cancer

Increased Travel Burden Decreases Likelihood of Receiving Radiation Therapy for Rectal Cancer Treatment

Increased travel distance to a cancer treatment facility negatively impacts the likelihood that patients with stage II/III rectal cancer will receive radiation therapy to treat their disease, according to a study analyzing 26,845 patient records from the National Cancer Data Base (NCDB) published...

colorectal cancer
solid tumors

Poorer Outcome With BRAF and KRAS Mutations in Microsatellite-Stable but Not Microsatellite-Unstable Colon Cancer

In an analysis of the PETACC-8 trial reported by Taieb et al in JAMA Oncology, BRAF V600 and KRAS mutations were associated with shorter disease-free and overall survival in patients with microsatellite-stable colon cancer—but not in those with tumors with microsatellite instability—in...

colorectal cancer
gastrointestinal cancer

Long-Term Follow-up of Prospective U.S. Cohorts Shows Reduced Risk of GI Tract Cancers With Regular Aspirin Use

In a long-term follow up of two large U.S. prospective cohorts reported in JAMA Oncology, Cao et al found that regular use of aspirin was associated with a reduced risk of gastrointestinal (GI) tract cancers. In 2015, the U.S. Preventive Services Task Force recommended the use of aspirin in...

colorectal cancer

Laboratory Study Explores How High-Fat Diet Influences the Development of Intestinal Tumors

A study published by Beyaz et al in Nature reveals how a high-fat diet makes the cells of the intestinal lining more likely to become cancerous. It joins a growing body of research that finds obesity and eating a high-fat, high-calorie diet are significant risk factors for many types of cancer....

colorectal cancer

High Expression of Epiregulin or Amphiregulin Predicts Benefit of Panitumumab in RAS Wild-Type Advanced Colorectal Cancer

In the UK phase III PICCOLO trial reported in JAMA Oncology, Seligmann et al found that high expression of either of the epidermal growth factor receptor (EGFR) ligands epiregulin or amphiregulin was associated with a progression-free survival benefit with panitumumab (Vectibix)/irinotecan vs...

colorectal cancer

ASCO’s Patient Resources for Colorectal Cancer Awareness Month

Stock your practice with Cancer.Net resources. Cancer.Net has a comprehensive guide to colorectal cancer at www.cancer.net/colorectal and a shorter, one-page colorectal cancer fact sheet. You will also find specialized resources for caregiving, survivorship, palliative care, and managing the cost...

colorectal cancer
issues in oncology

Half of Elderly Patients With Colorectal Cancer Receive Expensive Therapy With Little Survival Benefit

A study published by Bradley et al in Medical Care showed that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2% to 53%. During this period, 1-year treatment costs increased 32% to reach an...

colorectal cancer

Selective Internal Radiotherapy Does Not Improve Any-Site but Prolongs Liver-Specific Progression-Free Survival in Metastatic Colorectal Cancer

In the phase III SIRFLOX trial reported in the Journal of Clinical Oncology, van Hazel et al found that adding selective internal radiation therapy with yttrium-90 resin microspheres to FOLFOX (fluorouracil, leucovorin, oxaliplatin) with or without bevacizumab (Avastin) did not improve any-site...

colorectal cancer

Adding Immunotherapy to Radiofrequency Ablation in Colorectal Cancer With Liver Metastasis Shows Promise in Preclinical Models

In a retrospective case-controlled study conducted in patients with colorectal cancer who had received primary tumor resection with or without preoperative radiofrequency ablation for liver metastases, the electrical procedure was found to induce antitumor immune responses in the...

colorectal cancer

Factors Associated With Early Mortality in Patients Receiving Adjuvant Therapy for Colon Cancer

In an analysis of the ACCENT (Adjuvant Colon Cancer Endpoints) database reported in the Journal of Clinical Oncology, Cheung et al found that factors associated with early mortality in patients in trials of adjuvant systemic therapy included age, performance status, tumor grade, stage, and ratio of ...

Colorectal Cancer

Patients Diagnosed With Stage I to III Rectal Cancer at Younger Age Have Increased Risk for Positive Lymph Nodes

Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact treatment...

Colorectal Cancer

Shorter Radiation Course May Benefit Patients With Locally Advanced Rectal Cancer

As neoadjuvant treatment for locally advanced rectal cancer, a shorter course of radiation therapy followed by chemotherapy may be as good as, or better than, standard chemoradiotherapy, according to a study from the Polish Colorectal Study Group presented at the 2016 Gastrointestinal Cancers...

colorectal cancer
issues in oncology

Fecal Immunochemical Test Sensitive and Effective for Annual Colorectal Cancer Screening

Annual screening with the fecal immunochemical test is highly sensitive for detecting colorectal cancer and “is feasible and effective for population-level colorectal cancer screening,” according to a large-scale retrospective cohort study assessing the fecal immunochemical...

colorectal cancer
issues in oncology
issues in oncology

Updated Guidelines Recommend That Patients With Colorectal Cancer Undergo Colonoscopy After Cancer Resection

According to new recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer published by Kahi et al in Gastroenterology, postoperative colonoscopy is associated with improved overall survival for colorectal cancer patients. Therefore, it is critically important that colorectal...

colorectal cancer

Transcription Factor CDX2 May Be Prognostic Biomarker in Stage II and III Colon Cancer

In a study reported in The New England Journal of Medicine, Dalerba et al found that absence of the transcription factor CDX2, although prognostic for poor outcome in stage II and III colon cancer vs cancers with CDX2 expression, identified a subgroup of high-risk patients who appeared to benefit...

Colorectal Cancer

Dutch Trial Indicates 6-Year Surveillance Interval Is Sufficient for Many Individuals With Familial Colorectal Cancer

In a Dutch trial reported in the Journal of Clinical Oncology, Simone D. ­Hennink, MD, of Leiden University Medical Center in Leiden, the Netherlands, and colleagues found that a 6-year colonoscopic surveillance interval is sufficient for many individuals with familial colorectal cancer.1 However,...

colorectal cancer

Axel Grothey, MD, on Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer

Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.

Advertisement

Advertisement

Advertisement